Nature Medicine
1, 1130 - 1131 (1995)
doi:10.1038/nm1195-1130
No bones about fluorideGregory R. MundyDepartment of Medicine/Endocrinology & Metabolism, University of Texas Health Science Center, San Antonio, Texas 78284, USA We now have a number of effective drugs for osteoporosis. However, close inspection of clinical trials results suggests we should aim for even better ones.
REFERENCES
- Pak, C.Y. et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final update of a randomized controlled trial. Ann. intern. Med. 123, 401−408 (1995). | PubMed | ISI | ChemPort |
- Riggs, B.L. et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New Engl. J. Med. 322, 802−809 (1990). | PubMed | ISI | ChemPort |
- Kleerekoper, M. et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int. 1, 155−161 (1991). | ChemPort |
- Lau, K.H., Farley, J.R., Freeman, T.K. & Baylink, D.J. A proposed mechanism of the mitogenic action of fluoride on bone cells: Inhibition of the activity of an osteoblastic acid phosphatase. Metabolism 38, 858−868 (1989). | Article | PubMed | ISI | ChemPort |
- Reeve, J. et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trail. Br. Med. J. 280, 1340−1344 (1980). | PubMed | ISI | ChemPort |
- Grigoriadis, A.E. et al. c-fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443−448 (1994). | PubMed | ISI | ChemPort |
- Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693−702 (1991). | PubMed | ISI | ChemPort |
- Chavassieux, P.M., Arlot, M.E. & Meunier, P.J. Intersample variation in bone histomorphometry: Comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif. Tissue Int. 37, 345−350 (1985). | PubMed | ISI | ChemPort |
|
